/
Immunology
Graft Versus Host Disease
46
Pipeline Programs↗
89
Active Trials↗
44
Companies Involved↗
Graft Versus Host Disease is a moderately active landscape with 46 programs across 44 companies. The most active players are Astellas, MaaT Pharma. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical11
Phase 15
Phase 220
Phase 310
Approved
No programs
Analysis
Modality Breakdown
81%
Small molecule
30 of 37 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 98% of 46 pipeline programs.
Analysis
Trial Status
348
clinical trials
Completed152 · 44%
Terminated49 · 14%
Recruiting44 · 13%
Unknown status39 · 11%
Active, not recruiting26 · 7%
Not yet recruiting16 · 5%
Other22 · 6%
Clinical Trials
Trial Activity
348 trials
Page 1 of 24
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)